Moderna (NASDAQ:MRNA) Shares Gap Down – Should You Sell?

Posted by Francis Steltz on Sep 30th, 2026

Shares of Moderna, Inc. (NASDAQ:MRNA – Get Free Report) gapped down before the market opened on Wednesday. The stock had previously closed at $203.46, but opened at $186.55. Moderna shares last traded at $190.8560, with a volume of 6,389,386 shares changing hands.

Key Stories Impacting Moderna

Here are the key news stories impacting Moderna this week:

Positive Sentiment: Moderna appointed Juan Andres as chief operating officer as it prepares for the potential launch and commercial scale-up of its oncology candidate intismeran autogene. The move signals that management is building infrastructure for a more diversified, cancer-focused business. Jerh Collins will retire after four years with the company. Moderna Adds Chief Operating Officer Role as Company Expands into Oncology
Positive Sentiment: Investors continue to view Moderna’s cancer-vaccine program as a significant growth opportunity following encouraging Phase 3 results. Detailed melanoma data expected at the ESMO conference next month could provide an important catalyst, although the market is already pricing in considerable success. MRNA Stock Falls Premarket After Citi Downgrade
Neutral Sentiment: Citi raised its price target to $80 from $60 while changing its assumptions for sales and operating expenses, but still concluded that the stock’s current valuation is difficult to justify. This combination suggests expectations are high even under more favorable operating estimates. Moderna stock falls in premarket
Negative Sentiment: The downgrade reflects concern that available evidence for intismeran autogene is not yet strong enough to support Moderna’s elevated valuation. Investors may remain sensitive to the upcoming clinical readout because disappointing or merely adequate data could trigger further valuation pressure. Moderna Stock Has Run Too Far, Too Fast
Negative Sentiment: Moderna and Pfizer recently lost bids to exit Bayer’s U.S. mRNA patent lawsuit, leaving a potential legal and financial overhang for Moderna. Pfizer and Moderna lose bids in Bayer mRNA patent lawsuit

Analysts Set New Price Targets

Several equities analysts have recently commented on MRNA shares. Singular Research raised Moderna to a “hold” rating in a research note on Wednesday, September 23rd. Brookline Capital Markets reissued a “buy” rating on shares of Moderna in a research report on Wednesday, August 19th. Sanford C. Bernstein restated a “market perform” rating on shares of Moderna in a report on Friday. UBS Group reaffirmed a “neutral” rating on shares of Moderna in a research note on Tuesday, September 22nd. Finally, Bank of America raised shares of Moderna from an “underperform” rating to a “neutral” rating in a research note on Wednesday, August 19th. Seven equities research analysts have rated the stock with a Buy rating, thirteen have issued a Hold rating and five have issued a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $77.83.

View Our Latest Research Report on MRNA

Moderna Stock Down 8.0%

The company has a debt-to-equity ratio of 0.09, a quick ratio of 2.18 and a current ratio of 2.29. The firm has a market cap of $74.73 billion, a price-to-earnings ratio of -23.43 and a beta of 1.10. The firm has a 50-day moving average price of $117.42 and a two-hundred day moving average price of $76.99.

Moderna (NASDAQ:MRNA – Get Free Report) last announced its quarterly earnings results on Friday, July 31st. The company reported ($1.97) EPS for the quarter, topping the consensus estimate of ($2.03) by $0.06. Moderna had a negative net margin of 141.43% and a negative return on equity of 28.30%. The firm had revenue of $145.00 million for the quarter, compared to analyst estimates of $102.93 million. During the same period last year, the business earned ($2.13) EPS. Moderna’s revenue for the quarter was up 2.1% compared to the same quarter last year. On average, sell-side analysts forecast that Moderna, Inc. will post -6.09 earnings per share for the current year.

Insiders Place Their Bets

In other Moderna news, CFO James M. Mock sold 34,836 shares of the stock in a transaction that occurred on Thursday, September 10th. The stock was sold at an average price of $134.49, for a total transaction of $4,685,093.64. Following the completion of the sale, the chief financial officer directly owned 59,375 shares of the company’s stock, valued at approximately $7,985,343.75. This trade represents a 36.98% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, President Stephen Hoge sold 40,294 shares of the stock in a transaction on Monday, September 14th. The stock was sold at an average price of $144.13, for a total value of $5,807,574.22. Following the sale, the president directly owned 1,525,858 shares of the company’s stock, valued at approximately $219,921,913.54. This represents a 2.57% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 118,882 shares of company stock valued at $16,862,280. Insiders own 10.80% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of MRNA. QRG Capital Management Inc. grew its position in shares of Moderna by 16.8% in the second quarter. QRG Capital Management Inc. now owns 15,957 shares of the company’s stock valued at $1,117,000 after purchasing an additional 2,291 shares during the last quarter. Integrated Wealth Concepts LLC raised its position in shares of Moderna by 17.0% during the 2nd quarter. Integrated Wealth Concepts LLC now owns 7,653 shares of the company’s stock worth $536,000 after purchasing an additional 1,114 shares during the last quarter. NewEdge Advisors LLC lifted its stake in Moderna by 208.0% in the 2nd quarter. NewEdge Advisors LLC now owns 4,364 shares of the company’s stock valued at $306,000 after buying an additional 2,947 shares in the last quarter. Baird Financial Group Inc. grew its holdings in Moderna by 149.3% during the 2nd quarter. Baird Financial Group Inc. now owns 11,918 shares of the company’s stock valued at $835,000 after buying an additional 7,137 shares during the last quarter. Finally, Waverly Advisors LLC acquired a new stake in Moderna during the 2nd quarter valued at $243,000. Hedge funds and other institutional investors own 75.33% of the company’s stock.

Moderna Company Profile

(Get Free Report)

Moderna, Inc is a biotechnology company that develops medicines and vaccines using messenger RNA (mRNA) technology. Its platform is designed to instruct cells to produce proteins that can help prevent or treat disease, supporting the company’s work across infectious diseases, immuno-oncology, rare diseases, autoimmune conditions, and cardiovascular diseases.

Moderna’s commercial products include Spikevax, an mRNA vaccine for COVID-19, and mRESVIA, an mRNA vaccine for respiratory syncytial virus (RSV) in older adults.